Reaction profile

The FDA adverse-event record for digestive tract malabsorption disorder nos

16 FDA reports name digestive tract malabsorption disorder nos, a lower-volume reaction in the CVM extract (VeDDRA 324). Plate stamps and neighbourhood peers follow.

#2266 of 2,481
by report volume (all reactions)
16
reports citing this reaction
6.3%
death-coded share
Dog
most-affected species

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Digestive tract malabsorption disorder NOS has 16 reports now versus 16 in that prior snapshot: 0 the same number of (0.0%).

Report change
+0
Death-coded reports
+0
Death-coded share
+0.0 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Digestive tract malabsorption disorder NOS changes

FDA AER · VeDDRA plate

Code 324 VOL-TRACE

VOL-TRACE · DEATH-PAR · BOTTOM-DECILE · PHOTO-FINISH · SPECIES-DOG · DRUG-LEAD · DESK-WIDE · BOOK-FULL

  • VOL-TRACE 16 reports
  • DEATH-PAR 6.3%
  • BOTTOM-DECILE #2266/2481
  • PHOTO-FINISH Abdominal transudate
  • SPECIES-DOG Dog · 12
  • DRUG-LEAD Spinosad · 3
  • DESK-WIDE 14 breeds
  • BOOK-FULL 8/8 fields

Nearest volume peer: Abdominal transudate (±0 reports)

Instrument codes from this reaction’s FDA CVM adverse-event extract: volume band, death-coded share, corpus rank, photo-finish peer, lead species, lead drug, breed desk, and book completeness. Not a clinical diagnosis.

Lower-volume neighbourhood around Digestive tract malabsorption disorder NOS

Lower-third volume poles plus nearest peers, not a full reaction corpus board reprint.

Vomiting · highest174348Abdominal transudate · near16Abnormal rectal palpa… · near16AMMONIA INCREASED, BL… · near16Application site gran… · near16Digestive tract malab… · thi…16Urinary tract neoplas… · low…10
FDA AER report volume · neighbourhood around Digestive tract malabsorption disorder NOS

Digestive tract malabsorption disorder NOS: low death-coded share in the FDA AER plate

Signature read: 16 reports place Digestive tract malabsorption disorder NOS in the lower third of FDA AER volume (#2266 of 2,481). Report volume is lower-third scale: 16 named reports in the openFDA extract. Death-coded share is lower-third: 1 of 16 reports (6.3% of named reports). Nearest volume peer: Abdominal transudate (±0 reports). Lead species Dog (12). Lead co-reported drug Spinosad (3).

Read these counts as reporting volume, not risk: per our methodology, Lead co-reported drug Spinosad appears in filings alongside this reaction; that is association, not causation. Browse the full reactions index or the about page for how PlainBreed frames FDA CVM extracts.

Species Most Affected

Dog 12
Cat 2
Chicken 1
Horse 1

Breeds Most Affected

Domestic Shorthair 2
Retriever - Golden 2
Chicken (unknown) 1
Rottweiler 1
Dog (unknown) 1
American Pit Bull Terrier 1
Terrier - Norwich 1
Maltese 1
Retriever - Labrador 1
Terrier - Bull - American Pit 1

Associated Drugs

Spinosad 3
Oclacitinib Maleate 3
Narasin 1
Narasin + Nicarbazin 1
Ivermectin 1
Cefpodoxime Proxetil 1
Milbemycin Oxime + Spinosad 1
Nitenpyram 1
Imidacolprid And Moxidectin 1
Afoxolaner 1
Firocoxib 1
Cefovecin 1
Milbemycin Oxime + Praziquantel 1
Pyrantel Pamoate;Sarolaner 1
Afoxolaner 37.5Mg / Moxidectin 180Mcg / Pyrantel 75Mg Chewable Tablet 1

What to do with this reaction

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Digestive tract malabsorption disorder NOS (#2266 of 2,481 by report volume); death-coded 6.3%. PlainBreed reaction plate · report volume stamp 16 · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →